Transcript Wipo Regional Workshop on Patent Analytics  WIPO & INPI  Rio de Janeiro, August 26 a 28, 2013  Samples of Patent.

Wipo Regional Workshop on Patent Analytics
 WIPO & INPI
 Rio de Janeiro, August 26 a 28, 2013
 Samples of Patent Analytics
Observatory of Tecnologies - INPI/ Brazil
 Prof. Adelaide Antunes
 [email protected]
OBTEC
OBTEC / INPI
Observatory of Technologies
Strategic utilization of IP System in favor of
the economic development.
Created in 2010, the Observatory stimulates the interaction
between Brazilian Office and the several stakeholders of the
Brazilian National Innovation System (Universities, Research
Institutes, Finance Organizations, Government Agencies)
OBTEC
Wipo Regional Workshop on Patent Analytics
Observatory of Tecnologies - INPI/ Brazil
University (papers)
It´s necessary
 to identify the needs
 To develop a Strategy
 To search for information
 To analyse
INPI (Government)
Reports
Industries
(patents)
Innovation
 To disseminate
Economic Development
OBTEC
COOPERATION AGREEMENT
Partnership INPI – OBTEC / FINEP
(Funding Authority for Studies and Projects)
Observatory in the Health Sector
FINEP –goal: Introduce IP Culture
Brands / Patents
OBTEC
EX.: EMS
Patents
Patent documents x Priority year
Patent
Documents
7
3
4
patent documents
Priority
Country
Brazil
Great Britain
3
2
1
0
Major Generic
Drug Company
(80% incoming)
2003 2004
2005 2006
2007 2008 2009
2010 2011
priority year
Trademarks
Sector
Trademarks
(applications)
Pending
applications
Registered
trademarks
Dead
trademarks
Frist
Application
Latest
Application
Drugs
938
237
453
248
Nov., 1963
June, 2012
Company
EMS
OBTEC
STUDIES - DRUGS- FINEP
1
2
3
4
5
6
Capítulo da NCM
3004.90.68
3004.90.69
3004.39.27
3004.90.99
3004.90.68
3004.31.00
Grupo I - Tipo i
Medicamentos a base dos fármacos
Atazanavir
Ganciclovir
Gosserelina
Hidroxiuréia
Indinavir Sulfato
Insulina
7
3004.90.99
Isoniazida/Rifampicina/Pirazinamida/Etambutol
8
3004.39.81
Levotiroxina
9
3004.90.39
Mitoxantrona
10
3004.90.42
Talidomida
Regra de origem: salto de posição tarifária, exceto do capítulo 30
OBTEC
Ganciclovir
 RN: 82410-32-0
 IUPAC: 2-amino-1,9-dihydro-9-[[2-hydroxy-1(hydroxymethyl)ethoxy]methyl]-6H-Purin-6-one
 Therapeutic class: antiviral
 Names and brands
 2-Amino-1,9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]6H-purin-6-one
 Biolf 62
 BN-B759V
 Gansikloviiri
 Gansiklovir
 Gancyclovir
 Gancyklovir
 Ganecicilovir
 Gansikloviiri
 Gansiklovir
 HSDB 6512
OBTEC
Ganciclovir
 Labs Brasil (DEF)
Producers(DWCP) – 38
 Roche
 China - 24
 Halex Istar
 Índia - 4
 Blausiegel
 Alemanha - 3
 Lafepe
 Estados Unidos - 2
 Eurofarma
 Argentina, Brasil, Canadá,
França, Itália – 1
N º Priority documents / Country
China - 18
EUA - 5
Índia - 5
Escritório Europeu de Patentes - 2 (Itália e França)
Espanha e a Itália - 1 depósito cada.
OBTEC
COOPERATION AGREEMENT
Partnership INPI – OBTEC / FIOCRUZ
Oswaldo Cruz Foundation Science at Service of Life
Observatory in the Health Sector
OBTEC
Partnership INPI (OBTEC) / FIOCRUZ
 to identify global trends in cancer
 subsidize decision-making processes in the Brazilian healthcare
sector
Definition of (Brazilian) priorities
Important to know the Patent landscape on cancer drugs
 not-patented technologies
 patents that have expired
OBTEC
Partnership INPI (OBTEC) / FIOCRUZ
Derwent Innovations Index
Manual Code
B04-B04C4
B04-B04C8
B04-F02A
B04-K01S
B12-K04A1
B14-H01
B14-H01A
B14-H01B
B14-H01C
B14-H01D
B14-H01D1
B14-H01D2 /
B14-H01Z
B14-H01E
B14-H01E1.
B14-H01E2
B14-H01E3
B14-H01E4
B14-H01E5
B14-H01E6
B14-H01E7
Definição
Manual Code
Definição
B14-H01P
Multiple myeloma
Anticancer antibody B14-H01R
Oesophageal cancer
Cancer antigen
B14-H01S
Ovarian cancer
Cancer cells/Carcinoma
B14-H01T
Pancreatic cancer
Cancer cell or cancer cell antigen receptor
Diagnosis of tumours, cancer
B14-H01U
Prostate cancer
Anticancer general and other
B14-H01V
Rectal cancer
Manual Code
Definição
Leukaemia treatment
B14-H01W
Skin
melanoma
B14-H01E8
Stomach cancers
Antiproliferative, inhibitor of cell division, cytostatic
B14-H01X
Stomach cancer
B14-H01F
Genitourinary cancers
Dermatological cancers
B14-H01Y
Testicular cancer
B14-H01F1
Cervical/uterine cancers
Endocrine cancers
B14-H02
Mutagen, carcinogen
B14-H01F2
Kidney cancers
Breast cancers
B14-H03
Apoptotic
B14-H01F3
Ovarian cancers
Thyroid cancers
B14-H04
Anti-apoptotic
B14-H01F4
Prostate cancers
B14-H06
Radiosensitizers - Drugs to make tumour cells more
B14-H01F5 cancers
Testicular cancers
Gastrointestinal
sensitive to radiation therapy
B14-H01F6
Bladder cancers
Colon cancers
B14-S11C
Anticancer vaccine
B14-H01G
Immunological
cancers
Oesophageal cancers
B14-H01G1
linfoma de hodgkin
B04-G0500E
anticancer cell
Gall
bladder cancers
B14-H01G2
/
linfoma não-hodkin
B04-K01S0E
cancer cell/cancer cell antigen receptor
Intestinal cancers
B14-H01Q
Hepatic cancers
B04-F02A0E
cancer cells, carcinoma (mammalian)
B14-H01H
Musculoskeletal cancers
Pancreatic cancers
B12-G07
Anticancer
B14-H01H1
Osteocancers
Rectal cancers
B04-E02G /
Oncogene
B14-H01H2
Sarcoma
B04-E03G
B14-H01J
Neurological cancers
B14-H01J1
Brain tumours
B14-H01K
Oral and respiratory cancers
B14-H01K1
Buccal cavity and pharynx cancers
B14-H01K2
Larynx cancers
B14-H01K3
Lung cancers
B14-H01L
Other cancers
B14-H01L1
Multiple myelomas
B14-H01M
Larynx cancer
OBTEC
B14-H01N
Lung cancer
84.351 patent documents related
to cancer drugs (worldwide)
STUDIES
OBTEC
Scientific journal
call for papers: International Journal of Molecular
Sciences (2013)
Trends in Nanopharmaceutical Patents
Case Study
Adelaide Antunes1, Iolanda Fierro1, Rafaela Guerrante1, Flavia
Mendes2 and Maria Simone de M. Alencar3
1INPI; 2UFRJ
; 3FIOCRUZ
OBTEC
Methodology
 Data Base
Derwent Innovations Index
Main Advantages
 The summaries are full of keywords
 The possibility of exporting the patent documents recovered in the
search using software (Vantage Point)
 The availability of Manual Code related to nanotechnology
(classification attributed in the database to all patent documents
indexed in it)
 Selection of documents that were indexed between 2002 and
2012 in the Derwent database
OBTEC
Manual Codes related to nanotechnology applied to the
pharmaceutical sector, and the number of patent documents
Derwent manual
code
B12-M11Q
B12-M10A7
B11-C12
B05-U05A
B05-U05B
Description
Nanoparticles
Nanotechnology devices
Nanotechnology (general)
Nanotubes, nanorods or nanohorns
nanofilms
B05-U05C
Nanostructures, other than those
covered by B05-U05A and B05-U05B
B05-U05
B05-U04
B05-U03
Other carbon containing 3-D structures
Carbon plus heteroatom nanotubes
Carbon-only nanotubes
Number of patent
documents
2,306
160
5,028
Focus on Special
Issue “Bioactive
Nanoparticle 2012”
toxicity and nanoparticle
100
nano-imaging agent
44
40
615
nanoparticle for drug delivery
cancer-targeting nanoparticle
Removing the patent document that were in more than one of the nine series
OBTEC
Results
OBTEC
The main patent applicant by area
Total of
patents
Entity applying
for patents
Toxicity of
nanoparticle
Nanoimaging
agent
Nanoparticle
for drug
delivery
Cancertargeting
nanoparticle
23
Univ. of California
7
9
7
9
21
Massachusetts Inst. Technology
8
5
7
11
20
General Electric Co
10
20
0
0
16
Univ. Nat.
Tsing Hua
0
0
12
0
15
GP Medical Inc.
0
0
11
0
12
Univ. Texas System
0
6
5
6
8
Univ. Northwestern
0
0
0
6
8
Elan Pharma Int. Ltd
7
0
0
0
8
Konink Philips Electronics NV
0
8
0
0
7
Centre National de La Recherche
Scientifique (CNRS)
7
0
0
5
7
Abraxis Bioscience LLC
7
0
0
0
7
Fuji Film Co Ltd
0
0
6
0
6
Brigham & Women’s Hospital Inc.
0
0
0
6
5
Univ. Kyushu
0
0
5
0
OBTEC
MIT Partnerships
Auto-Correlation Map
Assignee Codes & Names :empre...
 MIT
BRIGHAM &WOM ENS HOSPITAL INC
 nanoparticles for use in
encapsulating a biologically active
agent (e.g., polynucleotide)
Links >= 0.000000 shown
> 0.75
1 (0)
0.50 - 0.75 0 (0)
0.25 - 0.50 2 (0)
< 0.25
7 (0)
IM M UNE DISEASE INST
Advantage is in effectively
providing low immunogenicity and
toxicity
HARVARD COLLEGE
CHILDRENS HOSPITAL BOSTON
UNIV NORTHWESTERN
Universities and Hospitals
M IT
GEN HOSPITAL CORP
UNIV CORNELL
OBTEC
Rethinking The Conceptual Base For New Practical
Applications In The Information Value And Quality (IGI Global
2014 USA)
Chapter 5 - The Contribution of Information
Science through Intellectual Property to
Innovation in the Brazilian Health Sector
Adelaide Maria de Souza Antunes, Flavia Maria Lins
Mendes, Suzanne de Oliveira Rodrigues Schumacher,
Luc Quoniam, Jorge Lima de Magalhães
OBTEC
Brazil Health System (SUS)
 Section 1: Pharmaceuticals industry, made up of six groups
 Group 1 – Antivirals (including antiretrovirals)
 Group 2 – Neglected Diseases
 Group 3 – Chronic non-communicable diseases
 Group 4 – Biological pathways
 Group 5 – Vaccines and Hemoderivatives
 Group 6 – Medications and inputs for the treatment of medical issues
resulting from nuclear accidents.
 Section 2: Medical devices and healthcare devices in general
OBTEC
Methodology
 Database used to access the patent documents: SciFinder
Scholar
 Search for each drug, using the CAS Registry Number
 Informations
 patents relating to processes (synthesis and/or formulation);
 main Applicants (assignees)
 top countries
 information about the first patent for the drug, date and respective
assignee
 patents filed in Brazil
 trends over time of patenting
OBTEC
Atorvastatin
 Atorvastatin (CAS RN: 134523-00-5)
 114 process patents
Patent Applications Filed for Atorvastatin
 84 are for its synthesis
18
 4 for its synthesis and formulation
 Companies with the most patents (eight each)
Number of Patents
16
 26 for its formulation
14
12
10
8
6
4
2
 Teva Pharmaceuticals Industries
 Warner-Lambert Company
0
1986 1989 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Priority Year
 First patent
 1986
Warner-Lambert Company
 Brazil (17 deposits)
 Warner Lambert Company (five for synthesis and one for formulation)
 Teva Pharmaceuticals Industries (one for formulation and one for synthesis)
 Pfizer (synthesis)
OBTEC
Calcitonin
 Calcitonin (CAS RN: 9007-12-9)
Patent Applications Filed for Calcitonin
 204 process patents
 Companies with the most patents
Number of Patents
 169 are for its synthesis
 28 for its formulation
 7 for its synthesis and formulation
14
12
10
8
6
4
2
0
 Armour Pharmaceutical (USA) - 9
Priority Year
 First patent
 1968
Ciba Ltd (Switzerland)
 Brazil (10 patents)
 2 for synthesis by Institut Gustave Roussy (France),
OBTEC
Scientific journal
III Academic Intelectual Property and Innovation
Development Meeting ( III ENAPID - INPI 2010)
Key Structures on Synthesis of HIV drugs
Adelaide Maria de Souza Antunes1, Rodrigo José Ávila
Cartaxo2, Flavia Maria Lins Mendes2
1INPI; 2UFRJ
OBTEC
19 HIV /
SciFinder (CAS/ACS)
Busca: RN
Top Applicants:
Merck & Co - 15 patentes
Bristol-Myers Squibb Co - 10 patentes
Technology domination:
54% em PCT
EUA – 40%
China, Índia e Japan – 41%
OBTEC
Methodology – 19 HIV
OBTEC
KEY Chemical Substances Analysis for HIVs
5-METHYLURIDINE
Zidovudine
O
O
S
R
HN
Estavudine
N3
N
S
R
OH
HN
O
O
N
S
OH
O
O
Me
2 routes
Bristol-Myers (US) and
Ajinomoto (JP)
Me
4 routes
Bristol-Myers, Ajinomoto, Japan
Tobacco and China Pharmacy Univ
24 producers :
16 China, 2 Canada, 2 USA, 1 Italy, 1 Korea, 1 Slovakia and 1 Rússia
OBTEC
Mapping technological knowlodge of ethanol 2º Generation
Thesis
Luiz André Felizardo S. Schlittler (EQ/UFRJ)
Advisers: Prof. Nei Pereira Jr./ Profa. Adelaide
Antunes(INPI)
OBTEC
Produção de etanol 2G
Enzymatic hydrolysis
Technological
focus
Genetic modification
micro-organims
Midwest R. Inst.
Univ. Florida
Enzyme production
Others compounds production
OBTEC
Technological Foresight applied
nanotechnology
Thesis
Maria Simone de Menezes Alencar (EQ/UFRJ)
Adviser: Adelaide Maria de Souza Antunes (INPI)
OBTEC
THERMS (strategy)
 Base de dados: Derwent Innovation Index
Termos selecionados
FULLERENES
NANOBELTS
NANOBIOLOGY
NANOBIOTECHNOLOGY
NANOCATALYST
NANOCOMPOSITE
NANOCORNS
NANOCRYSTAL
NANODROPLETS
NANODRUGS
NANOELECTRONICS
ESTRATÉGIA DE BUSCA
(fullerene*)
((nanobelt*) or (“nano belt*“))
((nanobiolog*) or (“nano biolog*“))
((nanobiotechnolog*) or (“nano biotechnolog*“) or
(bionanotechnolog*) or (“bio nanotechnolog*“))
((nanocatalys*) or (“nano catalys*“))
(nanocomposit* or (“nano composit*“))
((nanocorn* or “nano corn*“))
(nanocrystal* or (“nano crystal*“))
((nanodroplet*) or (“nano droplet*“))
((nanodrug* or “nano drug“*))
(nanoelectr* or (“nano electr*“))
OBTEC
Results
 Top countries
Evolução histórica dos países com maior número de depósitos de patentes
100%
90%
2958
4214
716
1659
997
80%
70%
60%
2002-2005
1999-2001
50%
1994-1998
40%
30%
20%
1179
1984
713
537
268
10%
471
343
11
223
33
0%
EUA
JAPÃO
CHINA
ALEMANHA
CORÉIA
OBTEC
Analysis
Classes CIP
n patentes Principais usos
H01L–semiconductor devices;
electric solid state devices not
otherwise provided
2870
C01B—non-metallic elements;
compounds thereof
2716
A61K—preparations for medical,
dental, or toilet purposes
1863
B82B—nano-structures;
manufacture or treatment thereof
chemistry
1615
B01J—chemical or physical
processes, e.g., catalysis, colloid
chemistry; their apparatus
1520
G01N—investigating or analyzing
materials by determining their
chemical or physical properties
1362
C08K—Use of inorganic or nonmacromolecular organic
substances as ingredients
1351
C08L—compositions of
macromolecular compounds
1134
H01J—electric discharge tubes or
discharge lamps
1128
Dispositivos eletrônicos
Dispositivos semicondutores
Células solares
Nanotubos de carbono
Células combustíveis
Catalisadores
Cancer (tratamento, medicação)
Cosmeticos
Drogas
Nanotubos de carbono
Dispositivos eletrônicos
Catalisadores
Catalisadores
Células combustíveis
Nanotubos de carbono
Proteinas
Ácidos Nucleicos
Anticorpos
Filmes
Revestimentos
Adesivos
Filmes
Revestimentos
Fibras
Field emission display
Nanotubos de carbono
Mostradores
Posição na nanocadeia de
valor
Nanointermediário
Nanointermediário
Nanoprodutos
Nanomatéria prima
Nanoprodutos
Nanointermediário
Nanoprodutos
Nanoprodutos
Nanoprodutos
Nanomatéria prima
Nanointermediário
Nanointermediário
Nanointermediário
Nanoprodutos
Nanomatéria prima
Nanomatéria prima
Nanomatéria prima
Nanomatéria prima
Nanointermediário
Nanointermediário
Nanointermediário
Nanointermediário
Nanointermediário
Nanointermediário
Nanointermediário
Nanomatéria prima
Nanointermediário
OBTEC
Patenting in The US
NANOPRODUCTUS: radiografia
industrial, sistemas óticos e de
imagem
NANOINTERMEDIATES:
biosensores, dispositivos
fotovoltaicos e para
armazenamento de memória
CLUSTER 1
NANOPRODUCTUS : com
aplicações em computadores,
filmes e automóveis
NANOPRODUCTUS dentais, adesivos
e revestimentos dentais e
equipamentos ortodônticos.
OBTEC
Agriculture
Innovation Strategy and Technology in Seeds
Estratégia de Inovação e Tecnologia em
Sementes.
Thesis
Rafaela Guerrante (EQ/UFRJ)
advisers: Prof. Nei Pereira Jr. e Profa. Adelaide
Maria de Souza Antunes
OBTEC
Case Study – Monsanto’s patents on GURT (genetic use
restriction technology)
 GURT technology
 colloquially known as terminator/traitor technology
 causes second generation seeds to be sterile  Terminator
 the use of an external chemical inducer which turns "on or off" a
plant's genetic traits (ex. sterility)  Traitor
 There are not specific keywords/IPCs to describe GURT
technology
 1224 Monsanto’s patent documents were retrieved, possibly
related to GURT
 In order to validate the results and analyze the technologies
described in the patents retrieved, a methodology was
developed.
OBTEC
Methodology 1st step
Reading of TITLE
and/or ABSTRACT
Reading of CLAIMS
and/or
DESCRIPTION
Reading of CLAIMS
and/or
DESCRIPTION
OBTEC
Methodology 2st step
Terminator
779 documents
“herbicide tolerance”
Filter using AND/OR
“resistance to”
“pest resistance”
“increased grain yield”
“tolerance to”
“increased growth rate”
DISCARD
14 documents
765 documents
NOT RELATED
Reading of CLAIMS
and DESCRIPTION
Filter - (“sterility” OR
“sterile”) ANDmale
DO NOT CONTAIN(“sterility” OR“sterile”)
ANDmale
756 documents
9 documents
8 documents
764 docs.related to
MALE-STERILITY
+
Reading of CLAIMS
and DESCRIPTION
1 doc.
NOT RELATED
OBTEC
Patent and Publications Networks related to
Dengue and HPV vaccines: its implications for
policy of innovation in health
Thesis
Priscila Rohem-Santos (IE/UFRJ)
Advisor: Claudia Inês Chamas
OBTEC
Survey design and data sources / Analysis
The search strategy encompasses definition of :
 keywords
 IPC and Derwent Manual codes
 database
The methodology of analysis involves:
I – Identification of Dengue and HPV
vaccine patent applications and articles;
II – Creation of clusters according to
various indicators such as applicant,
priority number, validity (legal status);
III – Claims' analysis of the applications
filed in Brazil.
IV – Social Network analysis
(coauthorsip/ corinventorship)
OBTEC
Survey design and data sources / Analysis
(3 databases for articles)
(3 databases for patents)
Merge results of diferent databases
Harmonization of names – Thesaurus
Ex.: merges/acquisition of pharamautical industries considering the
vaccine sector
(Aventis Pasteur + Pasteur Meriex Connaugth = Aventis Pasteur
(Sanofi) + Panacea + Shanta = Sanofi Pasteur (Homma et al, 2011)
Removal of duplicates
Adjacency matrices – correlation of
data
OBTEC
RESULTS: HPV articles and patents networks
BR
OBTEC
RESULTS: Dengue articles and patents
networks
Fragility of brazilian researchers’ conection
BR
OBTEC
Thanks!!!
Adelaide Antunes
[email protected]
Elaine Vianna
[email protected]
BernanrdoNunes
[email protected]
Cristina D’Urso
[email protected]
Priscila Rohem
[email protected]
Rafaela Guerrante
[email protected]
[email protected]
OBTEC